

Velcade[®] (bortezomib) – First-time generic

- On May 2, 2022, AuroMedics, Baxter Healthcare, Zydus, [Sagent Pharmaceuticals](#), [Apotex](#), [Gland Pharma](#), [Aurobindo/Eugia](#) and [Fresenius Kabi](#) launched AP-rated generic versions of Takeda's [Velcade \(bortezomib\)](#) injection.
 - In addition, [Teva](#) received FDA approval of AP-rated generic Velcade on May 2, 2022. The launch date for this generic manufacturer is pending.
- Velcade is approved for the treatment of adult patients with multiple myeloma and mantle cell lymphoma.
- According to IQVIA, Velcade had U.S. sales of ~\$1.2 billion for the 12 months ending March 2022.